May 27, 2020
Novartis Kisqali® shows overall survival benefit in HR+/HER2- advanced breast cancer with consistent findings in patients with more aggressive disease
May 11, 2020
AllianceRx Walgreens Prime studies the use of cyclin-dependent kinase 4/6 inhibitors in breast cancer patients
Nov 20, 2019
Biovica's DiviTum Validated as a Dynamic Biomarker in Metastatic Breast Cancer in Collaboration With Institut Curie, Paris
Sep 19, 2019
Addition of KISQALI® to drug plan in Quebec expands access to treatment for metastatic breast cancer
Sep 17, 2019
Mylan Expands Oncology Portfolio with Launch of Generic Faslodex® Injection, a Treatment for Advanced Breast Cancer
Sep 10, 2019
HR Positive/ HER2 Negative Breast Cancer Market Analysis, Market Size, Epidemiology, Leading Companies and Competitive Analysis by DelveInsight
Aug 22, 2019
CStone completes registration filing for the Phase I trial of CDK4/6 inhibitor CS3002 in Australia and will soon initiate the study
Apr 04, 2019
FDA expands approved use of metastatic breast cancer treatment to include male patients
Apr 19, 2018
Asembia Expands Collaboration with Pfizer Oncology
Feb 15, 2018
Quebec and New Brunswick Become First Provinces to Provide Public Funding of IBRANCE(TM) for the First-Line Treatment of Metastatic Breast Cancer
Nov 16, 2017
Global Cancer CDK Inhibitors Market & Clinical Pipeline 2017-2022 - $20 Billion Market Opportunity Assessment
Sep 28, 2017
FDA approves new treatment for certain advanced or metastatic breast cancers
Sep 05, 2017
MEI Pharma Announces Exclusive License Agreement with Presage Biosciences for Voruciclib, An Oral, Selective CDK Inhibitor
Jun 21, 2017
Pfizer Receives Expanded Health Canada Approval for IBRANCE® in HR+, HER2- Metastatic Breast Cancer